Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic CancerJulien Dilly, Andrew J. Aguirre, Brian M. Wolpin et al.|Cancer Discovery|2024Cited by 234
A neomorphic protein interface catalyzes covalent inhibition of RAS <sup>G12D</sup> aspartic acid in tumorsCaroline E. Weller, David Wildes, Lingyan Jiang et al.|Science|2025Cited by 31
Integrative genomic identification of therapeutic targets for pancreatic cancerJimmy A. Guo, Andrew J. Aguirre, Dennis Gong et al.|Cell Reports|2025Cited by 7
Abstract 2930: Intrinsic payload resistance governs responses to datopotamab deruxtecan, a TROP2 antibody drug conjugate, in pancreatic cancer model systemsPanot Sainamthip, Harshabad Singh, Kazuki Takahashi et al.|Cancer Research|2025Cited by 1
Supplemental Table 1 from Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic CancerJulien Dilly, Brian M. Wolpin, Megan T. Hoffman et al.|Unknown|2024Cited by 0